Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 9Active not recruiting 9Withdrawn 4Terminated 4Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 7Carcinoma, Merkel Cell 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Recurrence 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Cancer Resectable 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × avelumab × Clear all
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT04887831 2025-09-08

PRESERVE3

G1 Therapeutics, Inc.

Phase 2 Terminated
92 enrolled 24 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Case Comprehensive Cancer Center

Phase 2 Terminated
4 enrolled 10 charts
Genitourinary

Carcinoma, Transitional Cell

NCT03915405 2024-04-25

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Kyowa Kirin Co., Ltd.

Phase 1 Terminated
16 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡